Skip to content
20-F

Annual Report (Foreign)

BioLineRx Ltd. BLRX

0001178913-26-001581

← back to feed
Filed
Mar 23, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 2.47B sh
Shares Diluted FY 2025 · Dec 31, 2024 1.2B sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$8.07M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$43.87M
Cash And Equivalents FY 2025 · Dec 31, 2025 $3.25M
Cash And Equivalents FY 2025 · Dec 31, 2024 $10.44M
Stockholders Equity FY 2025 · Dec 31, 2025 $23.35M
Stockholders Equity FY 2025 · Dec 31, 2024 $13.46M
Current Liabilities FY 2025 · Dec 31, 2025 $12.12M
Current Liabilities FY 2025 · Dec 31, 2024 $15.41M
Total Liabilities FY 2025 · Dec 31, 2025 $17.56M
Total Liabilities FY 2025 · Dec 31, 2024 $25.45M
Current Assets FY 2025 · Dec 31, 2025 $23.68M
Current Assets FY 2025 · Dec 31, 2024 $27.1M
Total Assets FY 2025 · Dec 31, 2025 $40.91M
Total Assets FY 2025 · Dec 31, 2024 $38.91M
Eps Diluted FY 2025 · Dec 31, 2025 $0.00
Eps Diluted FY 2025 · Dec 31, 2024 −$0.01
Eps Basic FY 2025 · Dec 31, 2025 $0.00
Eps Basic FY 2025 · Dec 31, 2024 −$0.01
Sga Expense FY 2025 · Dec 31, 2025 $3.14M
Sga Expense FY 2025 · Dec 31, 2024 $6.32M
Rd Expense FY 2025 · Dec 31, 2025 $8.09M
Rd Expense FY 2025 · Dec 31, 2024 $9.15M
Net Income FY 2025 · Dec 31, 2025 −$2.03M
Net Income FY 2025 · Dec 31, 2024 −$9.22M
Operating Income FY 2025 · Dec 31, 2025 −$10.29M
Operating Income FY 2025 · Dec 31, 2024 −$20.41M
Gross Profit FY 2025 · Dec 31, 2025 $950K
Gross Profit FY 2025 · Dec 31, 2024 $19.68M
Cost Of Revenue FY 2025 · Dec 31, 2025 $230K
Cost Of Revenue FY 2025 · Dec 31, 2024 $9.26M
Revenue FY 2025 · Dec 31, 2025 $1.18M
Revenue FY 2025 · Dec 31, 2024 $28.94M